The increasing cases of spinal cord injuries and strategic initiatives by companies bolster the spinal cord stimulator devices market size. However, the high cost associated with spinal cord stimulator devices hinders the market growth.

Increasing Product Development Activities to Introduce New Trends in Spinal Cord Stimulator Devices Market in Coming Years

With advancements in medical knowledge and the introduction of effective medicines, a wide range of spinal cord stimulators are being used in treatments. In addition to the multiple advantages of these devices—including portability, convenience, and effectiveness—the growing number of product approvals and developments is expected to propel the demand for spinal cord stimulator devices in the coming years. A few of the major developments and approvals in the spinal cord stimulator device market are listed below:

• In October 2023, Boston Scientific Corp won approval from the US FDA for the WaveWriter Alpha SCS systems for the treatment of painful diabetic peripheral neuropathy (DPN), a disorder affecting the lower limbs of patients.
• In August 2023, Medtronic plc received CE (Conformité Européenne) Mark for its Inceptiv. The device is a closed-loop rechargeable spinal cord stimulator (SCS). It is the first SCS device of the company to offer a closed-loop feature. Inceptive is equipped with technology that can sense each patient’s unique biological signals, adjust stimulation as per the patient’s moment, and offer harmonized therapy with the motions of daily life.
• In August 2022, Abbott Laboratories received approval from the US FDA for its Proclaim Plus SCS system to treat chronic pain. The device is enabled with the BurstDR stimulation technology to deliver superior pain relief. It offers FlexBurst360 therapy that offers pain coverage across the trunk and limbs; the device can be programmed as per the patient’s evolving therapeutic needs.
• In September 2020, Boston Scientific announced the launch of the WaveWriter Alpha portfolio of spinal cord stimulator (SCS) Systems in the European market. The portfolio comprises four MRI, Bluetooth-enabled implantable pulse generators (IPGs), along with additional personalization options based on patients’ needs. These systems are available in rechargeable/non-rechargeable options, which cover multiple areas of pain.

Thus, such advancements by various market players and product approvals catalyze the growth of the spinal cord stimulator devices market.

North America held the largest share of the global spinal cord stimulator devices market in 2022 owing to technological advancements, an increasing number of spinal cord injuries, government support for the expansion of the product pipeline, and the presence of major market players engaged in new and existing product developments. However, Asia Pacific is anticipated to register the highest CAGR during 2022–2030. The US held the largest share of the spinal cord stimulator devices market in North America in 2022. Growth of the market in the US is mainly driven by a surging incidence of spinal cord injuries, an increasing number of product launches, and favorable initiatives by governments. According to Spinal Cord Inc., ~18,000 people suffer from spinal cord injuries every year in the US. The National Spinal Cord Injury Statistical Center (NSCISC) states that ~320,000 people are living with traumatic spinal cord injury in the US. In line with the increasing cases of spinal cord injuries in the US, several technologically advanced spinal cord stimulator devices have been approved by the US Food and Drug Administration. In December 2022, Abbott received the FDA approval for the company’s Eterna spinal cord stimulation (SCS) system. It is the smallest implantable, rechargeable spinal cord stimulator available in the market for the treatment of chronic pain.

Spinal Cord Stimulator Devices Market: Competitive Landscape and Key Developments

Boston Scientific Corp, Nevro Corp, Abbott Laboratories, Cirtec Medical Corp, Medtronic Plc,  Biotronik SE & Co KG, Curonix LLC, Nalu Medical Inc, and Synapse Biomedical Inc. are a few key companies operating in the spinal cord stimulator devices market. Market players adopt product innovation strategies to meet evolving customer demands, thereby maintaining their brand names in the spinal cord stimulator devices market.

A few of the recent developments in the global spinal cord stimulator devices market are mentioned below: In December 2022, the Eterna spinal cord stimulation (SCS) system from Abbott Laboratories is now available for the treatment of chronic pain. Abbott’s low-dose BurstDR stimulation, a patented low-dose SCS waveform technology with the greatest level of clinical evidence, has been approved by the FDA. Additionally, it has been demonstrated that the technique aids in 23% more pain reduction than the results produced by conventional waveform technology-based methods.